TAVI PROGRAM CHANGING THE EDMONTON LANDSCAPE...
|
|
- Terence White
- 6 years ago
- Views:
Transcription
1 TAVI PROGRAM CHANGING THE EDMONTON LANDSCAPE... Benjamin Tyrrell MD, FRCPC Co-Director TAVI Program Northern Alberta CK HUI Heart Centre NOV 29, 2014
2 Disclosures None related to this talk
3 Objectives Brief Review of TAVI Rationale for TAVI Local Data Future Directions
4 Case 85 year old female with SOB on exertion with murmur High functioning Mild Renal Insufficiency DM diet controlled Remote smoker quit 30 years ago TIA
5 Physical Exam Systolic Murmur Diamond-Shaped, harsh, left sternal border to right intercostal spaces, neck and apex Late peak, obliteration of S2 Pulses Parvus Tardus Delayed and Low Volume Carotid Pulse
6 Symptoms of Aortic Stenosis Angina Syncope or Presyncope Dyspnea
7 ECHO
8 ECHO
9 ECHO
10 ECHO
11 ECHO
12 Hemodynamics
13 Aortic Stenosis - Etiology Bicuspid Inflammatory/ Rheumatic Degenerative/ Calcific
14 Pathophysiology AS develops gradually over 4me LV adapts to pressure overload with concentric hypertrophy
15 Prognosis of AS Survival ayer onset of symptoms is 50% at two years and 20% at five years 1 Surgical interven4on [for severe AS] should be performed promptly once even minor symptoms occur 2 Source: 1 S.J. Lester et al., The Natural History and Rate of Progression of Aor4c Stenosis, Chest C.M. OMo, Valve Disease: Timing of Aor4c Valve Surgery, Heart 200 Chart: Ross J Jr, Braunwald E. Aor4c Stenosis. Circula4on. 1968;38(Suppl 1):61-7.
16 Standard Therapy
17 Medical RX Beta Blockers Diuretics Supplemental Oxygen Statin? Aortic Valvuloplasty
18 What is TAVI?
19 What is TAVI? Transcatheter Aortic Valve Implantation invented in first in man (Dr. Cribier)
20 What is TAVI? Transcatheter Aortic Valve Implantation invented in first in man (Dr. Cribier)
21 What is TAVI? Transcatheter Aortic Valve Implantation invented in first in man (Dr. Cribier)
22 September 22, 2010 on NEJM.org
23 PARTNER Study Design
24 PARTNER Study Design Symptomatic Severe Aortic Stenosis ASSESSMENT: High Risk AVR Candidate 3105 Total Patients Screened
25 PARTNER Study Design Symptomatic Severe Aortic Stenosis ASSESSMENT: High Risk AVR Candidate 3105 Total Patients Screened Total = 1058 patients n= 700 High Risk 2 Parallel Trials: Inoperable n=358 Individually Powered
26 PARTNER Study Design Symptomatic Severe Aortic Stenosis ASSESSMENT: High Risk AVR Candidate 3105 Total Patients Screened Total = 1058 patients n= 700 High Risk 2 Parallel Trials: Inoperable n=358 Individually Powered ASSESSMENT: Transfemoral Access High Risk TF High Risk TA 1:1 Randomization 1:1 Randomization TAVI Trans femoral VS Surgical AVR TAVI Trans femoral VS Surgical AVR Primary Endpoint: All Cause Mortality (1 yr) (Non-inferiority)
27 PARTNER Study Design Symptomatic Severe Aortic Stenosis ASSESSMENT: High Risk AVR Candidate 3105 Total Patients Screened Total = 1058 patients n= 700 High Risk 2 Parallel Trials: Inoperable n=358 Individually Powered ASSESSMENT: Transfemoral Access ASSESSMENT: Transfemoral Access High Risk TF High Risk TA 1:1 Randomization 1:1 Randomization 1:1 Randomization Not In Study TAVI Trans femoral VS Surgical AVR TAVI Trans femoral VS Surgical AVR TAVI Trans femoral VS Standard Therapy (usually BAV) Primary Endpoint: All Cause Mortality (1 yr) (Non-inferiority) Primary Endpoint: All Cause Mortality over length of trial (Superiority)
28 All Cause Mortality Standard Rx TAVI All-cause mortality (%) Months Numbers at Risk TAVI Standard Rx
29 All Cause Mortality Standard Rx TAVI at 1 yr = 20.0% NNT = 5.0 pts All-cause mortality (%) 50.7% 30.7% Months Numbers at Risk TAVI Standard Rx
30 All-Cause Mortality (ITT) Crossover Patients Censored at Crossover Standard Rx (n = 179) TAVR (n = 179) 80.9% 87.5% 93.6% All-Cause Mortality (%) 50.8% 30.7% 68.0% 43.0% 53.9% 64.1% HR [95% CI] = 0.50 [0.39, 0.65] p (log rank) < % Months * In an age and gender matched US population without comorbidities, the mortality at 5 years is 40.5%.
31 TAVR Mortality Stratified by Age (ITT) 96.0% 91.8% 73.5% 70.4% Mortality (%) Months
32 Median Survival 11.1 Months p (log rank) < Months Months
33 Repeat Hospitalization (ITT) Standard Rx (n = 179) TAVR (n = 179) 83.0% 87.3% 72.5% 75.7% Rehospitalization (%) 53.9% 34.9% 43.1% 46.3% 47.6% 27.0% HR [95% CI] = 0.40 [0.29, 0.55] p (log rank) < Months
34 Subgroup Analysis All-Cause Mortality Hazard Ratio [95% CI] Overall (N=358) 0.50 [ ] Age < 85 (N=186) 0.46 [ ] Age 85 (N=172) 0.56 [ ] Male (N=166) 0.46 [ ] Female (N=192) 0.55 [ ] BMI 25 (N=170) 0.58 [ ] BMI > 25 (N=188) 0.44 [ ] STS 11 (N=170) 0.52 [ ] STS > 11 (N=187) 0.53 [ ] EF 55 (N=173) 0.47 [ ] EF > 55 (N=171) 0.61 [ ] Pulmonary Hypertension No (N=136) 0.56 [ ] Yes (N=103) 0.51 [ ] Mod / Sev MR No (N=261) 0.58 [ ] Yes (N=77) 0.30 [ ] Oxygen Dependent COPD No (N=270) 0.46 [ ] Yes (N=88) 0.68 [ ] Prior CABG or PCI No (N=182) 0.55 [ ] Yes (N=176) 0.46 [ ] Interaction p-value
35 Primary Endpoint: All-Cause Mortality at 1 Year TAVR AVR No. at Risk TAVR AVR Months
36 Primary Endpoint: All-Cause Mortality at 1 Year TAVR AVR No. at Risk TAVR AVR Months
37 Primary Endpoint: All-Cause Mortality at 1 Year TAVR AVR 26.8 HR [95% CI] = 0.93 [0.71, 1.22] P (log rank) = No. at Risk TAVR AVR Months
38 Both TAVR and AVR were associated with important but different periprocedural hazards: Major strokes at one year (5.1% vs. 2.4%, p=0.07) major vascular complications were more frequent with TAVR (11.0% vs. 3.2%, p<0.001) Major bleeding (9.3% vs. 19.5%, p<0.001) and new onset atrial fibrillation (8.6% vs. 16.0%, p<0.001) were more frequent with AVR TAVR and AVR are both acceptable therapies in these high-risk patients
39 Worldwide Transcatheter Aortic Valve Implantation First implantable aortic valve ,000 TAVI annually worldwide Market estimates 200,000 TAVI candidates representing $2B market by 2014
40 Inception of Heart Team TAVI team Multidisciplinary combining Interventional Cardiology and Cardiac Surgery Regional collaboration between CK Hui and MAHI Directors: Welsh,Tyrrell and Meyer Echo Dr. Shanks CT Drs. Butler & Sidhu
41 Pa4ent Journey Pt severe AS Clinical Visit Anatomy Tavi Review Open AVR Medical RX 29
42 SCREENING for TAVI
43 All SAPIEN XT Valve Sizes Available
44 All SAPIEN XT Valve Sizes Available
45 TAVR Transfemoral and Transapical Transfemoral Transapical
46
47
48
49
50
51
52
53
54 Percutaneous Closure
55 LOCAL DATA 140" 120" 100" 80" 60" 40" 20" 0" TAVI%CLINIC%REFERRALS% 79 to AVR 108 Rejected All" 31)Dec)09" 31)Dec)10" 31)Dec)11" 31)Dec)12" 31)Dec)13" 31)Dec)14" 1)Jan)09" 1)Jan)10" 1)Jan)11" 1)Jan)12" 1)Jan)13" 1)Jan)14" 531 patients in total
56 All Across Canada Edmonton Rural Sask Manitoba BC NWT NFLD YUKON
57 Local Data 45" 40" 35" 30" 25" 20" 15" 10" 5" 0" Completed)Cases)/)Fiscal)Year)Total) 31(Mar(11" 31(Mar(12" 31(Mar(13" 31(Mar(14" Completed"Cases"/"Fiscal" Year"Total" 1(Apr(10" 1(Apr(11" 1(Apr(12" 1(Apr(13" 173 completed TAVI
58 Cases By Age 85.50% 85.00% Mean%Age% % 84.00% 83.50% Mean%(all)% 83.00% 82.50% 82.00% Both% TF% TA% Range 54 to 98 years of Age
59 Procedural DATA 98.8% successful implants 5.8% pacemaker implant rate <1% clinical significant stroke 1 peri-procedural death at day 3 post TAVI
60 Approach for TAVI Majority are Trans-femoral 60.06% male TF 14% TA Size%Total% 86% 23#mm#(total)# 23#mm#(valve-in-valve)#AV# 26#mm#(total)# 26#mm#(valve-in-valve)#AV# 29#mm#(total)# 29#mm#(valve-in-valve)#AV#
61 Mortality 180" 160" 140" 120" 100" 80" 60" 40" 20" 0" Completed" Vital&Status&Total& Alive" Decease"(0+"days)"TOTAL" Decease"(0>7"days)" Decease"(7>30"days)" Decease"(0>30"days)" Decease"(>30"days)" Vital"Status"Total"
62 Mortality 35" 30" 33 25" 20" 15" 10" 5" " Decease"(0-7"days)" Decease"(7-30" days)" Decease"(0-30" days)" Decease"(>30"days)"
63
64 Mortality All#Cases# TA# 1" 2" Completed) Alive) TF# 1" 2" 18.5% mortality
65 Length of Stay 2011 TAVI%to%Discharge% (Average)% 25# 20 20# 15# 10# 5 8 TF#(F)# 13 TA#(M)# TA#(F)# 5# TF#(M)# 0# TF#(M)# TF#(F)# TA#(M)# TA#(F)#
66 AVG LOS POST TAVI 2014 POST TAVI NON TAVI ALL TF TA
67 Reducing Complica4ons BeMer technology BeMer case selec4on Experience BeMer results 50
68 Edwards esheath Expandable Introducer Sheath
69 Dynamic Expansion Mechanism Allows the sheath to expand, then return to a reduced profile once the valve has passed through the sheath Unexpanded Expanded Reduced Profile
70 CVA Risk age>70 DM HTN Hyperlipidemia Aor4c Calcifica4on Aortic Artheroma 53
71 Embrella Embolic Deflector Porous membrane designed to deflect embolic debris Nitinol Frame & Shaft Polyurethane Porous Membrane Hydrophillic coating with antithrombogenic properties 3 Radiopaque Markers 54
72 Cerebral vessel coverage
73 Variety of Captured & Removed Emboli 56
74 BeMer Valve Skirt to reduce Paravalvular leak Procedural planning and sizing using CT 57
75
76 3M Approach to TAVR A Multidisciplinary, Multimodality, but Minimalist (3M) approach to Transfemoral TAVR facilitates safe next day discharge in high risk patients Safe next day discharge after minimally invasive heart valve surgery
77 Less is more Maximize objective functional and anatomical screening followed by a Minimalist procedure
78 3M Approach to TAVR Functional Screening 25% Procedural Expertise 50% Anatomical Screening 25%
79 3M TAVR Functional Assessment* Frailty >5 TUG Functional > 20 seconds Screening 5 metre > 6 seconds 25% MMSE < 26 ADL > 1 IADL > 2 Home Supports 3M Approach to TAVR Procedural Expertise 50% Anatomical Screening 25%
80 3M TAVR Functional Assessment* Frailty >5 TUG Functional > 20 seconds Screening 5 metre > 6 seconds 25% MMSE < 26 ADL > 1 IADL > 2 Home Supports 3M TAVR Procedural Coaxial Checklist valve plane Adequate TTE images (pvl and complications) Area based Anatomical CT sizing Screening with root assessment (adequate 25% images) Iliofemoral assessment (CT) No Foley Minimize Lines (Anesthesia) Early Mobilization 3M Approach to TAVR Procedural Expertise 50%
81 3M TAVR Discharge Criteria No persistent IVCD (if present, consider POD 2 discharge) Mobilizing at baseline (access sites) Follow up blood work Day 3 and Day 5 (Hgb < 100, egfr < 30) TTE (POD 1) Home Supports Contact Information (30 days)
82
83 30 Day VARC 2 Outcomes (n = 60)
84 30 Day VARC 2 Outcomes (n = 60) Death 1 (1.7%) MI 0 (0%) CVA (All) 0 (0%) Major 0 (0%) Minor 1 (1.9%) Major 0 (0%) Minor 2 (3.3%) AKI 0 (0%) PPM 2 (3.3%) Device 58 (97%)
85 Parting Words Just because something is a class 3 indication doesn t mean you should stop doing it... Dr. Randy Williams Canadian Cardiovascular Congress Nov 2014
A new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center
A new option for the Diagnosis and Management of Valvular Heart Disease Oregon Comprehensive Valve Center I have no disclosures Oregon Comprehensive Valve Center Weekly multidisciplinary case conferences
More informationFive-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial
Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationTAVI After PARTNER-2 : The Hamilton Approach
TAVI After PARTNER-2 : The Hamilton Approach James L. Velianou MD FRCPC Interventional Cardiology Hamilton General Hospital St Catharines General Hospital Associate Professor of Medicine McMaster University
More informationTranscatheter Aortic Valve Replacement TAVR
Transcatheter Aortic Valve Replacement TAVR Paul Gordon, MD Associate Prof of Medicine, Brown University Director, Cardiac Catheterization Laboratory The Miriam Hospital Disclosures: none 100 Symptomatic
More informationTHE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON
THE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON INTRODUCTION History of heart valve intervention Current indications
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More informationTAVR IN INTERMEDIATE-RISK PATIENTS
TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS
More informationTAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre
TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre Disclosure St. Jude Medical: Consultant and Proctor Edwards Lifesciences: Proctor Medtronic: Research
More informationThe Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center
The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health Adam J. Saltzman, MD Cardiovascular Care Center Southcoast Health Disclosures Edwards Lifesciences: speaking honorarium Outline
More informationAn Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.
An Update on the Edwards TAVR Results Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. Luke s Hospital Disclosures On the speaker s bureau for Endologix, TriVascular,
More informationIgor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
More informationAortic Stenosis: Open vs TAVR vs Nothing
Aortic Stenosis: Open vs TAVR vs Nothing Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More informationUpdate on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center
Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock
More informationTAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
More informationCase Presentations TAVR: The Good Bad and The Ugly
Case Presentations TAVR: The Good Bad and The Ugly Vincent J. Pompili, MD, FACC, FSCAI Professor of Internal Medicine Director of Interventional Cardiovascular Medicine and Cardiac Catheterization Laboratories
More informationAortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?
Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationAortic Stenosis Background and Breakthroughs in Treatment: TAVR Update
Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Howard J Broder MD Interventional Cardiology DaVita Medical Group/ Healthcare Partners Cardiology Disclosures for Howard J Broder
More information2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR
TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of
More informationTAVR in Intermediate Risk Populations /Optimizing Systems for TAVR
TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai
More informationRANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING
AORTIC VALVE DISEASE RANDOMISED TRIALS COMPARING TAVI WITH SAVR STEPHAN WINDECKER DEPARTMENT OF CARDIOLOGY SWISS CARDIOVASCULAR CENTER AND CLINICAL TRIALS UNIT BERN BERN UNIVERSITY HOSPITAL, SWITZERLAND
More informationDebate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI
Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular Surgery University of Pennsylvania Immediate
More informationNeal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries
More informationTranscatheter Valve Therapies Update
Providence Heart and Vascular Institute Transcatheter Valve Therapies Update Where In The H*@# Is All This Going??? Robert Hodson MD Medical Director, Providence Valve Center October 24, 2015 DISCLOSURES
More informationEstablishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS
Establishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T h e Pa
More informationPERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES
PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES Dr.Vinny K.Ram No disclosures TAVR 1 Lesson number 1:
More informationTRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH
TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH Available systems: Edwards (TA and TF) and Core valve. INTRODUCTION 3 4% 0f > 65 y. 30 40% of elderly denied surgery,.
More informationTranscatheter Valve Replacement: Current State in 2017
Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP
More informationValve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.
Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D. Professor, Thoracic and Cardiovascular Surgery University of Florida klodell@surgery.ufl.edu Disclosures
More informationStructural Heart Disease Transcatheter Aortic Valve Replacement (TAVR)
Structural Heart Disease Transcatheter Aortic Valve Replacement (TAVR) Kathleen Harper DO FACC FACP 87 Chief, Cardiology Section VA Maine Healthcare Kathleen.Harper@va.gov Prevalence of Aortic Stenosis
More informationTAVI: Present and Future Perspective
TAVI: Present and Future Perspective Igor F. Palacios, M.D. Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School Percutaneous transcatheter
More informationValvular Intervention
Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone
More informationPercutaneous Management of Severe AS in Octagenarians. Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington
Percutaneous Management of Severe AS in Octagenarians Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington May 2017 Outline Aetiology of AS Natural History of AS Assessment
More informationTrans Catheter Aortic Valve Replacement
Trans Catheter Aortic Valve Replacement Satish K Surabhi, MD,FACC,FSCAI Medical Director, Cardiac Cath Labs AnMed Health Heart and Vascular Care No financial conflict of interest related to this talk Will
More informationIntegrating Innovative Technologies into the Care of Cardiac Patients
Integrating Innovative Technologies into the Care of Cardiac Patients Marc J. Semigran MD Medical Director, Heart Failure & Cardiac Transplantation MGH Associate Professor Harvard Medical School Presenter
More informationTAVR: Intermediate Risk Patients
TAVR: Intermediate Risk Patients Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital & Favaloro University
More information1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
More informationThe Future of TAVR: Minimalist Fast Track
The Future of TAVR: Minimalist Fast Track Zvonimir Krajcer, MD Program Director- Peripheral Vascular Interventions Department of Cardiology, St. Luke s Episcopal Hospital and Texas Heart Institute, Houston,
More informationResults of Transapical Valves. A.P. Kappetein Dept Cardio-thoracic surgery
Results of Transapical Valves A.P. Kappetein Dept Cardio-thoracic surgery Rotterda am, The Netherlands 2002 FIM 2003 2005 2006 2010 THV THV Cribier-Edwards Edwards Edwards Sapien Sapien XT Bovine pericardium
More informationLOW RISK TAVR. WHAT THE FUTURE HOLDS
LOW RISK TAVR. WHAT THE FUTURE HOLDS Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Allison Family Distinguish Chair of Cardiovascular Research Houston Methodist DeBakey Heart & Vascular
More informationTAVR SPRING 2017 The evolution of TAVR
TAVR SPRING 2017 The evolution of TAVR Matthew Johnson, MD Disclosers None Evolution of the Balloon- Expandable Transcatheter Valves Cribier 2002 SAPIEN 2006 SAPIEN XT 2009 SAPIEN 3 2013 * Sheath compatibility
More information2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route
Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National
More informationTranscatheter procedures of the future; expanding the treatment options for patients with severe aortic stenosis
Transcatheter procedures of the future; expanding the treatment options for patients with severe aortic stenosis John Webb MD Director interventional cardiology, St Paul s Hospital McLeod Professor of
More informationDisclosures. LGH TAVR: Presentation Outline 2/2/2016. Updates in Transcatheter Aortic Valve Replacement (TAVR) and the LGH Experience
Updates in Transcatheter Aortic Valve Replacement (TAVR) and the LGH Experience The LGH TAVR Program James E. Harvey, MD, MSc Medical Director, Structural Heart Intervention The Heart Group of Lancaster
More informationSAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes
SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes Howard C. Herrmann, MD on behalf of The PARTNER II Trial
More informationPrince Sultan Cardiac Center Experience Riyadh, Saudi Arabia
Transcatheter Transapical Aortic Valve Implantation Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia Ahmed Elwatidy, MD,PhD, FRCS S Kassab, MD,S Ahmari, MD, H Amri, MD, H Ismail, MD, A Calafiori,
More informationMinimalist Transcatheter Aortic Valve Replacement (MA-TAVR)
Minimalist Transcatheter Aortic Valve Replacement (MA-TAVR) Jensen HA, Condado JF, Devireddy C, Binongo JN, Leshnower BG, Babaliaros V, Sarin EL, Lerakis S, Guyton RA, Stewart JP, Syed AQ, Mavromatis K,
More informationTranscatheter Therapies For Aortic Valve Disease. March 2017 Brian Whisenant MD
Transcatheter Therapies For Aortic Valve Disease March 2017 Brian Whisenant MD Introduction I got into this field to protect my turf. I must say, I have come full circle... - Kent W. Jones I got into this
More informationEvolving and Expanding Indications for TAVR
Evolving and Expanding Indications for TAVR Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationIs TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients
Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Cedars Sinai Heart Institute, Los Angeles, CA Potential
More informationAortic valve implantation using the femoral and apical access: a single center experience.
Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany
More informationLe TAVI pour tout le monde?
Le TAVI pour tout le monde? Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or
More informationTAVI: Nouveaux Horizons
TAVI: Nouveaux Horizons EUAPI580i 432HQ14NP02353 Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Objectifs Les recommandations Le TAVI en chiffre La
More informationEdwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved
Transcatheter Aortic Valve Replacement Symptomatic Aortic Stenosis Asymptomatic Juan Crestanello, MD Interim Director, Division of Cardiac Surgery Associate Professor Division of Cardiac Surgery The Ohio
More information22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2.
Oxford City Transcatheter aortic valve replacement 2017 guidelines Monday 19 th June Jim Newton Oxford Oxford University Hospitals NHS FT How familiar are you with TAVR? 1. First time I have heard about
More informationAortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC
Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC No Financial Disclosures Aortic Stenosis AS is an insidious disease with a long latency period followed by
More informationIs Stroke Frequency Declining?
Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac
More informationAortic Stenosis: Background
Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic
More informationDavid Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS. Peripheral Complications of TAVR
David Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS Peripheral Complications of TAVR TAVR Complications Reported Complications Rates range from 8% to 15% Predictors of
More informationAssessment and Preparation of Patients with TAVI. Rob Tanzola Associate Professor, Queen s University
Assessment and Preparation of Patients with TAVI Rob Tanzola Associate Professor, Queen s University My patient has aortic stenosis and needs non-cardiac surgery Should (s)he get a TAVI? Rob Tanzola Associate
More informationAppropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK
Appropriate Use of TAVR - now and in the future A Surgeon s Perspective Neil Moat Royal Brompton Hospital, London, UK Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner
More informationSurgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea
Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea Contents Decision making in surgical AVR in old age Clinical results of AVR with tissue valve Impact of 19mm
More informationAortic Valve Practice Guidelines: What Has Changed and What You Need to Know
Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts
More informationDisclosures 4/16/2018. What s New in Valvularand Structural Heart Disease. None relevant to the presentation
What s New in Valvularand Structural Heart Disease Ryan C. Shelstad, MD Surgical Enthusiast, Valvular and Structural Heart Disease Bryan Heart Cardiothoracic Surgery Disclosures None relevant to the presentation
More informationWhen Should We Consider TAVI. (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea
When Should We Consider TAVI Procedure in Korea (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea Aortic Stenosis in Korea Rapidly increasing valve disease in Korea Still low incidence
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationTAVI: Transapical Procedures
Cardiology Update Davos TAVI: Transapical Procedures Volkmar Falk, MD University Hospital Zürich TA-AVI: antegrade, simple, safe The front door approach! Transapical TAVI Technical advantages of TA approach
More informationParis, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators
Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo
More informationMatthew R. Reynolds, M.D., M.Sc. On Behalf of the PARTNER Investigators
Lifetime Cost Effectiveness of Transcatheter Aortic Valve Replacement Compared with Standard Care Among Inoperable Patients with Severe Aortic Stenosis: Results from the PARTNER Trial (Cohort B) Matthew
More informationΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012
ΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012 TAVR Technologies Current Generation Devices ~ 50,000 patients treated thru 2011 in > 500 interventional centers
More informationHow Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min
2016 ASE State of the Art Echocardiography Course Tucson, AZ How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, 2016 11:00 11:25 PM 25 min 1 M U H A M E D S A R I Ć, M D, P H D
More informationAlternate Vascular Access for TAVR. Gian Paolo Ussia Campus Bio-medico University, Rome Italy
Alternate Vascular Access for TAVR Gian Paolo Ussia Campus Bio-medico University, Rome Italy g.ussia@unicampus.it REQUIRED Gian Paolo Ussia I have no relevant financial relationships Transcatheter Valves
More informationAustralia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes
Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes A/ Professor Darren Walters On behalf of the ANZ Source Investigators Director of Cardiology Brisbane, Australia ANZ
More informationCardiolucca Heart Celebration. Seconda generazione delle valvole e miglioramento degli outcome nel trattamento percutaneo della stenosi aortica
Cardiolucca 2014 Heart Celebration Seconda generazione delle valvole e miglioramento degli outcome nel trattamento percutaneo della stenosi aortica Sergio Berti Ospedale del Cuore Fondazione C.N.R. Reg.
More informationSaudi Heart Association. Raising Standards through Education and Training
Saudi Heart Association Raising Standards through Education and Training 25th Annual Meeting EACTS Lisbon, Oc ctober 2011 WWW EA WWW. ACTS ORG ACTS.ORG Clinical decision making in case of Aortic valve
More informationTranscatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients:
Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 1-Year Results from the SURTAVI Clinical Trial Nicolas M. Van
More informationSevere Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative
Severe Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative Samin K. Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationStrokes After TAVR. Ioannis Iakovou, MD, PhD. Interventional Cardiology Onassis Cardiac Surgery Center
Strokes After TAVR Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Strokes After TAVR How common is stroke after TAVR Is it increasing? Is it more with TF vs TA? Is it
More information7 th Conference of Transcatheter Heart Valve Therapies
7 th Conference of Transcatheter Heart Valve Therapies May 18-19, 2018, Athens Hilton Athens, Greece Course Directors Stratis Pattakos MD Konstantinos Spargias MD Panos Vardas MD Co-Directors Nick Bouboulis
More informationAfter PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
More informationMulticentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system
Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Preliminary Results: Acute and 1-year Outcomes Ganesh Manoharan, MBBCh, MD, FRCP Consultant Cardiologist
More informationEssential Support for a Structural Heart Program: The Valve and Structural Heart Clinic
Essential Support for a Structural Heart Program: The Valve and Structural Heart Clinic Vincent Varghese, DO, FACC, FSCAI Director, Interventional Cardiology Fellowship Program Deborah Heart and Lung Center
More informationTAVR: Review of the Robust Data from Randomized Trials
TAVR: Review of the Robust Data from Randomized Trials Nicholas J. Ruggiero II, MD,FACP, FACC, FSCAI, FSVM, FCPP Director, Structural Heart Disease and Non-Coronary Interventions Director, Jefferson Heart
More informationHeart Team For TAVI Who and How?
2 nd TAVI Summit 2012, Seoul Corea Heart Team For TAVI Who and How? Alain Cribier, MD, Charles Nicolle Hospital University of Rouen, France Disclosure Edwards Lifesciences Consultant Training / proctoring
More informationAortic Valve Stenosis and TAVR: Putting it all together.
Aortic Valve Stenosis and TAVR: Putting it all together. Maria L. Held, MSN CNS Valve Clinic Coordinator at The Cleveland Clinic Alliance of Cardiovascular Professionals April 14 th, 2018 Brief Anatomy
More informationThe Silent and Apparent Neurological Injury in Transcatheter Aortic Valve Implantation Study (SANITY)
The Silent and Apparent Neurological Injury in Transcatheter Aortic Valve Implantation Study (SANITY) Jonathon Fanning, Allan Wesley, Darren Walters, Eamonn Eeles, David Platts, John Fraser The University
More informationStainless Steel. Cobalt-chromium
Sapien is better than Corevalve! Raj R. Makkar, MD Associate Director, Cedars-Sinai Heart Institute Associate Professor, UCLA School of Medicine, Los Angeles Eberhard Grube: Pioneer in the field of TAVR
More informationValvular Heart Disease and Adult Congenital Intervention. A Pichard, MD. Director Cath Labs, Washington Hospital Center. Georgetown University.
Valvular Heart Disease and Adult Congenital Intervention. A Pichard, MD Director Cath Labs, Washington Hospital Center. ProfessorofMedicine (Cardiology), Georgetown University. Conflict of Interest Proctor
More informationTranscatheter Aortic Valve Implantation Present Status and Perspectives
Transcatheter Aortic Valve Implantation Present Status and Perspectives Angioplasty Summit TCTAP 2010 Alain Cribier, MD University of Rouen, France Transcatheter Aortic Valve Implantation has entered the
More informationThe Role of TAVI in high-risk and normal-risk Patients
The Role of TAVI in high-risk and normal-risk Patients Joachim Schofer Hamburg University Cardiovascular Center and Department for percutaneous treatment of structural heart disease Albertinen Heart Center
More informationEmergency TAVI: Does It Exist? Is the Risk Higher?
Emergency TAVI: Does It Exist? Is the Risk Higher? Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia APCASH 12 October 2014 Disclosure Statement of
More informationPercutaneous aortic valve replacement should NOT be preferred therapy for aortic stenosis
Percutaneous aortic valve replacement should NOT be preferred therapy for aortic stenosis James Bartholomew McClurken, MD FACC, FCCP, FACS, FESC Professor & Vice-Chair of Surgery, Temple University Hosp.,
More informationPercutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update
Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update T. Lefèvre Natural History of Aortic Stenosois 100 Latent period Survival (%) 80 60 40 20 Symptoms Average Age Death 0 40 50
More informationEdwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?
Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval? Update from PARTNER EU and SOURCE Registries T. Lefèvre Disclosure Statement Cardiologist Interventional cardiologist 1 st PABV in
More informationNY STATE NPA 33 rd Annual Conference TAVR & Structural Heart Update
NY STATE NPA 33 rd Annual Conference TAVR & Structural Heart Update October 21, 2017 Rose Hansen DNP Structural Heart Coordinator Gates Vascular Institute, Buffalo NY TAVR Update: Objectives 1. Understand
More information